-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Stock Rating Lowered by TheStreet
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Stock Rating Lowered by TheStreet
TheStreet cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) from a c- rating to a d rating in a research note published on Tuesday morning, TheStreetRatingsTable reports.
A number of other brokerages have also recently commented on CALT. Kepler Capital Markets began coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 16th. They set a buy rating for the company. Pareto Securities began coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 2nd. They set a buy rating for the company.
Get Calliditas Therapeutics AB (publ) alerts:Calliditas Therapeutics AB (publ) Stock Up 1.9 %
Shares of NASDAQ:CALT opened at $15.75 on Tuesday. The business has a 50-day moving average price of $18.21 and a 200 day moving average price of $17.80. Calliditas Therapeutics AB has a 12-month low of $12.55 and a 12-month high of $32.24. The company has a market capitalization of $465.87 million, a price-to-earnings ratio of -6.33 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64.
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
An institutional investor recently raised its position in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC increased its holdings in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,762 shares of the company's stock after purchasing an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned approximately 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 at the end of the most recent quarter. Institutional investors own 2.94% of the company's stock.Calliditas Therapeutics AB (publ) Company Profile
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Further Reading
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
TheStreet cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) from a c- rating to a d rating in a research note published on Tuesday morning, TheStreetRatingsTable reports.
據The StreetRatingsTable報道，在週二上午發佈的一份研究報告中，華爾街將Calliditas治療公司(Publ)(納斯達克代碼：CALT-GET評級)的股票從C級下調至D級。
A number of other brokerages have also recently commented on CALT. Kepler Capital Markets began coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 16th. They set a buy rating for the company. Pareto Securities began coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 2nd. They set a buy rating for the company.
其他一些券商最近也對CALT發表了評論。開普勒資本市場在6月16日星期四的一份報告中開始報道Calliditas Treateutics AB(Publ)。他們為該公司設定了買入評級。帕累託證券在6月2日星期四的一份報告中開始報道Calliditas Treateutics AB(Publ)。他們為該公司設定了買入評級。
Calliditas Therapeutics AB (publ) Stock Up 1.9 %
Calliditas Treateutics AB(Publ)股價上漲1.9%
Shares of NASDAQ:CALT opened at $15.75 on Tuesday. The business has a 50-day moving average price of $18.21 and a 200 day moving average price of $17.80. Calliditas Therapeutics AB has a 12-month low of $12.55 and a 12-month high of $32.24. The company has a market capitalization of $465.87 million, a price-to-earnings ratio of -6.33 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64.
納斯達克：CALT的股票週二開盤報15.75美元。該業務的50日移動均線價格為18.21美元，200日移動均線價格為17.80美元。Calliditas Treateutics AB的12個月低點為12.55美元，12個月高位為32.24美元。該公司市值為4.6587億美元，市盈率為-6.33倍，貝塔係數為1.63。該公司的流動比率為5.32，速動比率為5.32，債務權益比率為0.64。
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
對衝基金買入Calliditas Treateutics AB(Publ)
Calliditas Therapeutics AB (publ) Company Profile
Calliditas Treateutics AB(Publ)公司簡介
(Get Rating)
(獲取評級)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Calliditas Treateutics AB(Publ)是一家臨牀階段的生物製藥公司，專注於識別、開發和商業化用於孤兒適應症治療的藥物產品，最初的重點是腎臟和肝臟疾病。它提供Nefecon，一種口服布地奈德製劑，是一種治療自身免疫性腎病免疫球蛋白A腎病的免疫抑制劑。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- 免費獲取StockNews.com關於Calliditas Treateutics AB(Publ)(CALT)的研究報告
- 石油和天然氣股票：投資可再生能源的安全途徑
- 這些綠色能源公司適合你的投資組合嗎？
- 希捷科技的宿醉何時才能結束？
- 安相能源有足夠的動力繼續提高動力嗎？
- 獨一無二的氫燃料電池庫存
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Calliditas Treateutics AB(Publ)Daily的新聞和評級-在下面輸入您的電子郵件地址，以通過MarketBeat.com的免費每日電子郵件時事通訊接收對Calliditas Treateutics AB(Publ)和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧